Company news

Savara, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Savara to Participate in Three Upcoming Investor Conferences

November 8, 2022

Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022

September 5, 2022

Savara to Present at H.C. Wainwright 24th Annual Global Investment Conference

August 31, 2022

Savara Announces Resignation of Chief Medical Officer

August 25, 2022

Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

August 24, 2022

Savara Reports Second Quarter 2022 Financial Results and Provides Business Update

August 10, 2022

Savara Announces Acceptance of Three Abstracts at the European Respiratory Society (ERS) International Congress 2022

July 10, 2022

Savara Awarded Innovation Passport in United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim), a Novel Investigational Inhaled Biologic

June 15, 2022

Savara to Present at Jefferies Healthcare Conference

May 31, 2022

Savara to Present at H.C. Wainwright Global Investment Conference

May 16, 2022

Savara Reports First Quarter 2022 Financial Results and Provides Business Update

May 10, 2022

Savara Announces Debt Refinancing of $26.5M Credit Facility With Silicon Valley Bank

April 21, 2022

Savara Reports Fourth Quarter / Year-End 2021 Financial Results and Provides Business Update

March 29, 2022

Savara to Present at Oppenheimer’s 32nd Annual Healthcare Conference

March 8, 2022

Savara to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

January 3, 2022

Savara to Participate in Two Upcoming Investor Healthcare Conferences

November 14, 2021

Savara Reports Third Quarter 2021 Financial Results and Provides Business Update

November 11, 2021

Savara to Present at the Inaugural Piper Sandler Lung Day

October 6, 2021

Savara Announces New Employment Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

September 2, 2021

Savara Reports Second Quarter 2021 Financial Results and Provides Business Update

August 11, 2021

Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial

June 29, 2021

Savara to Present at the Jefferies Virtual Healthcare Conference

May 25, 2021

Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit

May 16, 2021

Savara Reports First Quarter 2021 Financial Results and Provides Business Update

May 12, 2021

Savara Announces Closing of $130 Million Public Offering Following Full Exercise of Underwriters’ Option

March 14, 2021

Savara Announces Pricing of Public Offering of Common Stock

March 10, 2021

Savara Announces Proposed Public Offering of Common Stock

March 9, 2021

Savara Provides Pipeline and Business Update

December 9, 2020

Savara Announces Participation in Fireside Chats at Two Upcoming Virtual Investor Healthcare Conferences

November 23, 2020

Savara to Present at the Jefferies Virtual London Healthcare Conference

November 10, 2020

Savara Reports Third Quarter 2020 Financial Results and Provides Business Update

November 4, 2020

Savara Announces Senior Management Changes

September 10, 2020

Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held Virtually

September 8, 2020

Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study Results

September 7, 2020

Savara to Discontinue Exploratory ENCORE Study Evaluating Molgradex for the Treatment of NTM Lung Infection in People Living With Cystic Fibrosis (CF)

September 2, 2020

Savara Reports Second Quarter 2020 Financial Results and Provides Business Update

August 5, 2020

Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually

August 4, 2020

Savara to Report Second Quarter 2020 Financial Results and Provide Business Update

July 29, 2020

Savara to Present at the Jefferies Virtual Healthcare Conference

May 26, 2020

Savara Announces Change of Date for 2020 Annual Meeting of Stockholders

May 7, 2020

Savara Reports First Quarter 2020 Financial Results and Provides Business Update

May 6, 2020

Savara to Report First Quarter 2020 Financial Results and Provide Business Update

April 29, 2020

Savara Obtains Global Rights to Develop and Commercialize Apulmiq

April 1, 2020

Savara Provides Business Update in Response to COVID-19 Pandemic

March 29, 2020

Savara Reports Fourth Quarter / Year-End 2019 Financial Results and Provides Business Update

March 11, 2020

Savara to Report Fourth Quarter/Year-End 2019 Financial Results and Provide Business Update

March 4, 2020

Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

December 29, 2019

Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million

December 19, 2019

Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors

December 2, 2019

Savara’s COO and CMO to Present at the Evercore ISI 2nd Annual HealthCONx Conference

November 25, 2019

← Newer news releases · Older news releases →

Decks

The 5 newest of 65 decks. Every deck is listed under its year.